» Articles » PMID: 30159679

Identification of Small Molecule Inhibitors of ALK2: a Virtual Screening, Density Functional Theory, and Molecular Dynamics Simulations Study

Overview
Journal J Mol Model
Publisher Springer
Specialty Molecular Biology
Date 2018 Aug 31
PMID 30159679
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Bone morphogenetic proteins (BMPs) are a family of more than 30 ligands and several receptors, such as activin like kinases (ALKs) and bone morphogenetic protein receptor (BMPR). Physiological significance of these proteins lies in their prominent role during homeostasis, apoptosis, tissue remodeling, embryonic patterning, and normal development. Fibrodysplasia ossificans progressive (FOP) is one among several other diseases caused by impaired BMP signaling. FOP is caused by the pathogenicity of activating mutation of ALK2. In order to treat FOP, a search for good inhibitors of ALK2 based on dorsomorphin and LDN substitution, which in essence is a ligand based search of inhibitors, is in progress. Contributing to this area of research we identified several lead molecules based on protein structure using virtual screening. After virtual screening of a huge library of small molecules and ab initio calculation of selected molecules for drug efficacy, we did molecular dynamic simulation of lead molecules and protein complexes. We identified five potential drug molecules that show very stable binding on the same binding site as LDN-213844. We also ranked these lead molecules based on MM/PBSA binding energy. This study provides a basis to think beyond the pyrimidine nucleus of dorsomorphin/LDN and design new chemical derivatives for effective treatment of FOP. Graphical abstract Small molecule inhibitors of ALK2.

Citing Articles

Computational screening of chemical constituents derived from berry fruits as allosteric caspace-3/-7 inhibitors.

Ahmad Ansari W, Khan M, Hasan S, Siddiqui Z, Ahmad S, Khan M 3 Biotech. 2024; 14(10):234.

PMID: 39297056 PMC: 11405617. DOI: 10.1007/s13205-024-04067-7.

References
1.
Lee Y, Cheng C, Bilen M, Lu J, Satcher R, Yu-Lee L . BMP4 promotes prostate tumor growth in bone through osteogenesis. Cancer Res. 2011; 71(15):5194-203. PMC: 3148283. DOI: 10.1158/0008-5472.CAN-10-4374. View

2.
Shi S, Hoogaars W, de Gorter D, van Heiningen S, Lin H, Hong C . BMP antagonists enhance myogenic differentiation and ameliorate the dystrophic phenotype in a DMD mouse model. Neurobiol Dis. 2010; 41(2):353-60. PMC: 3674857. DOI: 10.1016/j.nbd.2010.10.003. View

3.
Mohedas A, Xing X, Armstrong K, Bullock A, Cuny G, Yu P . Development of an ALK2-biased BMP type I receptor kinase inhibitor. ACS Chem Biol. 2013; 8(6):1291-302. PMC: 3901569. DOI: 10.1021/cb300655w. View

4.
Steinbicker A, Sachidanandan C, Vonner A, Yusuf R, Deng D, Lai C . Inhibition of bone morphogenetic protein signaling attenuates anemia associated with inflammation. Blood. 2011; 117(18):4915-23. PMC: 3100698. DOI: 10.1182/blood-2010-10-313064. View

5.
Shi Y, Massague J . Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell. 2003; 113(6):685-700. DOI: 10.1016/s0092-8674(03)00432-x. View